An interventional study of Modified USPHS criteria in Class V Dental Caries, sponsored by Cairo University. Status unknown. Open to participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-07-20.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
The aim of the study is to clinically evaluate the shade matching and clinical performance of the Universal shade composites Omnichroma and GC Essentia versus the multi shade composite Filtek Z350XT in restoring cervical lesions of anterior teeth.
1,109 studies on the registry are indexed under Dental Caries; 197 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 916 interventional studies indexed under Dental Caries.
Browse Dental Caries studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Diagnostic Test: Modified USPHS criteria
Diagnostic Test: Modified USPHS criteria
Diagnostic Test: Modified USPHS criteria
It assess the restorations with visual inspection using a mirror and explorer. It includes Marginal integrity, shade matching, retention, marginal discoloration, gingival inflammation, and recurrent caries.
Clinical performance (USPHS criteria)
USPHS criteria
Time frame: baseline: 1 week
Clinical performance (USPHS criteria)
USPHS criteria
Time frame: 6 months
Clinical performance (USPHS criteria)
USPHS criteria
Time frame: 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University